ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Mental Health
Tamoxifen for bipolar disorder: Systematic review and meta-analysis
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Nelson Vergel" data-source="post: 139751" data-attributes="member: 3"><p>Tamoxifen for bipolar disorder: Systematic review and meta-analysis</p><p>Show all authors</p><p>Jorge Palacios, Ayşegül Yildiz, Allan H Young, ...</p><p>First Published February 11, 2019 Research Article </p><p><a href="https://doi.org/10.1177/0269881118822167" target="_blank">SAGE Journals: Your gateway to world-class journal research</a></p><p>Article information </p><p> Article has an altmetric score of 24 No Access</p><p>Abstract</p><p>Background:</p><p>Tamoxifen is an oral medication that has been proposed as a potential treatment for bipolar disorder. Tamoxifen acts to inhibit the intracellular action of protein kinase C, which is also an action of well-established treatments such as lithium and valproate. Here we aimed to identify randomised controlled trials (RCTs) of tamoxifen in the treatment of bipolar disorder and synthesise their results using meta-analysis.</p><p></p><p>Methods:</p><p>RCTs were identified by searching of electronic databases and from discussion with experts in the field. Data were extracted, and meta-analyses performed in R.</p><p></p><p>Results:</p><p>Five placebo-controlled RCTs of tamoxifen in the treatment of acute mania were identified. There were no trials in the treatment of episodes of bipolar depression, or for relapse prevention. The studies of mania treatment were of between three and six weeks duration. Tamoxifen was studied either as monotherapy (two trials) or as augmentation of lithium or valproate (three trials). Change in mania scale scores favoured tamoxifen over placebo: SMD −2.14 (95% CI −3.39 to −0.89; 4 trials), as did endpoint mania scale scores SMD 1.23 (95% CI 0.60–1.87; 5 trials). Response rates were also higher: RR 4.35 (1.99–9.50; 4 trials). Acceptability was similar to placebo: RR 1.03 (0.94–1.13; 5 trials).</p><p></p><p>Conclusions:</p><p>Tamoxifen appears to be a promising potential treatment for episodes of mania. Future studies could investigate its effects as an adjunct to dopamine antagonists for improved anti-manic efficacy, and establish its longer-term effects on mood, particularly depression and relapse.</p><p></p><p><a href="https://journals.sagepub.com/doi/abs/10.1177/0269881118822167?journalCode=jopa&" target="_blank">SAGE Journals: Your gateway to world-class journal research</a></p></blockquote><p></p>
[QUOTE="Nelson Vergel, post: 139751, member: 3"] Tamoxifen for bipolar disorder: Systematic review and meta-analysis Show all authors Jorge Palacios, Ayşegül Yildiz, Allan H Young, ... First Published February 11, 2019 Research Article [URL="https://doi.org/10.1177/0269881118822167"]SAGE Journals: Your gateway to world-class journal research[/URL] Article information Article has an altmetric score of 24 No Access Abstract Background: Tamoxifen is an oral medication that has been proposed as a potential treatment for bipolar disorder. Tamoxifen acts to inhibit the intracellular action of protein kinase C, which is also an action of well-established treatments such as lithium and valproate. Here we aimed to identify randomised controlled trials (RCTs) of tamoxifen in the treatment of bipolar disorder and synthesise their results using meta-analysis. Methods: RCTs were identified by searching of electronic databases and from discussion with experts in the field. Data were extracted, and meta-analyses performed in R. Results: Five placebo-controlled RCTs of tamoxifen in the treatment of acute mania were identified. There were no trials in the treatment of episodes of bipolar depression, or for relapse prevention. The studies of mania treatment were of between three and six weeks duration. Tamoxifen was studied either as monotherapy (two trials) or as augmentation of lithium or valproate (three trials). Change in mania scale scores favoured tamoxifen over placebo: SMD −2.14 (95% CI −3.39 to −0.89; 4 trials), as did endpoint mania scale scores SMD 1.23 (95% CI 0.60–1.87; 5 trials). Response rates were also higher: RR 4.35 (1.99–9.50; 4 trials). Acceptability was similar to placebo: RR 1.03 (0.94–1.13; 5 trials). Conclusions: Tamoxifen appears to be a promising potential treatment for episodes of mania. Future studies could investigate its effects as an adjunct to dopamine antagonists for improved anti-manic efficacy, and establish its longer-term effects on mood, particularly depression and relapse. [URL="https://journals.sagepub.com/doi/abs/10.1177/0269881118822167?journalCode=jopa&"]SAGE Journals: Your gateway to world-class journal research[/URL] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Mental Health
Tamoxifen for bipolar disorder: Systematic review and meta-analysis
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top